Prediction model establishment for the status of recurrent laryngeal nerve lymph node after neoadjuvant therapy in esophageal cancer
10.3969/j.issn.1002-1671.2024.06.007
- VernacularTitle:食管癌新辅助治疗后喉返神经旁淋巴结状态预测模型构建
- Author:
Zexue PENG
1
;
Baodan LIANG
;
Fengze WU
;
Shumin ZHOU
;
Yizhuo LI
;
Lizhi LIU
Author Information
1. 湘雅常德医院放射科,湖南 常德 415600
- Keywords:
esophageal cancer;
neoadjuvant therapy;
recurrent laryngeal nerve lymph node;
computed tomography
- From:
Journal of Practical Radiology
2024;40(6):888-892
- CountryChina
- Language:Chinese
-
Abstract:
Objective To construct a prediction model for post-neoadjuvant therapy recurrent laryngeal nerve lymph node(RLN LN)status via clinical and CT image data in esophageal cancer patients pre-neoadjuvant therapy.Methods A retrospective analysis was conducted on 403 patients with locally advanced esophageal cancer who received neoadjuvant therapy and radical resection for esophageal cancer.All patients were divided into a training cohort(n=270)and a validation cohort(n=133)randomly according to a 2:1 ratio.Clinical and imaging features associated with positive RLN LN pathology were selected by univariate analysis.Multivariate logistic stepwise regression model was used to construct the prediction model.The prediction ability of the model was evaluated by receiver operating characteristic(ROC)curve.Results The basic model included neoadjuvant therapy and RLN LN short diameter,with an area under the curve(AUC)of 0.7(training cohort)and 0.65(validation cohort).The final prediction model included neoadjuvant therapy,human albumin,platelet count,largest lymph node enhancement characteristics,whether the largest lymph node was in the recurrent laryngeal region,and RLN LN short diameter,with AUC of 0.83[95％confidence interval(CI)0.768-0.899]and 0.76(95％CI 0.645-0.887)for the training and validation cohorts,respectively.Conclusion The model based on clinical data and imaging features pre-neoadjuvant therapy for esophageal cancer can assist in clinically predicting the post-neoadjuvant therapy RLN LN status.
